Taiwan's China Airlines postpones retirement of older planes due to Boeing 787 delays
TAOYUAN: Taiwan's China Airlines is postponing the retirement of some of its older aircraft due to delays in getting Boeing 787-9 jets that may result in compensation payments from the planemaker, the carrier's newly appointed chairman said.
Taiwan's oldest airline, established in 1959, is in the midst of a fleet renewal, last year splitting an order for new long-haul aircraft worth almost US$12 billion at list prices between Boeing and European rival Airbus.
China Airlines has also ordered 24 Boeing 787s for regional and some longer-distance routes, including 18 787-9s and six of the stretched 787-10 variant.
But Chairman George Kao (pic) said China Airlines' fleet renewal plan to replace ageing Airbus A330s and Boeing 737-800s with 787-9s and A321neos was being hit by delays in getting new aircraft delivered, especially the 787-9s.
"We are at present being greatly impacted. Some aircraft that were scheduled to be phased out, or handed back at the end of their lease, as some are leased, will remain and have their leases extended," he told Reuters in an interview at the airline's headquarters in Taoyuan, home to Taiwan's main international airport.
Boeing has not given China Airlines an exact timeframe for the 787-9 delays, though it has said deliveries will "basically" start from the end of 2025, added Kao, a pilot by training who started out as a flight attendant and became chairman in March.
"This is written into the contract," he said, when asked whether China Airlines would seek compensation.
"For example, if it's in the supply chain, the responsibility is Boeing's, and Boeing has to provide some compensation. But if it's not, then there is no compensation. It's all recorded in the contract."
Boeing did not respond to a request for comment.
Other airlines are facing similar issues.
International Air Transport Association (IATA) Director General Willie Walsh, whose group represents airlines globally, this month called predictions of aircraft delivery delays throughout this decade "off-the-chart unacceptable".
Still, Kao was upbeat about expansion plans, pointing to the more fuel-efficient 777-9s and A350-1000s ordered last year that will enable more capacity to be added to routes like New York and London, and a new third terminal at Taoyuan airport, the first section of which is expected to open later this year.
He signalled further aircraft additions ahead for subsidiary Mandarin Airlines, which flies almost exclusively domestic routes with ATR-72 turboprops and is getting a revamp to focus on regional routes from southern and central Taiwan with new jet aircraft.
"I can talk about this with aircraft lessors," he said, without disclosing the jet models it could add. "We have this plan, to let Mandarin Airlines grow up."
China Airlines faces competition at home not only from long-established rival EVA Air but also rapidly growing Starlux Airlines, which last week placed an order for ten more A350s.
Kao said while the Taiwan market itself was small, transit traffic, which all three airlines are focusing on, meant supporting three full-service airlines was not an issue.
Seoul's Incheon airport is too big, meaning passengers can get lost, Tokyo's landing fees are too expensive and Hong Kong has "political issues", whereas Taoyuan airport's new terminal will greatly improve the travel experience, he said.
"Our passengers are not all Taiwanese; many are transit. Because Taiwan's location, connecting the Pacific to all of Asia, is really very convenient." - Reuters
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
an hour ago
- The Star
Virgin Australia shares soar 8.3% on IPO debut
The IPO attracted strong demand, with institutional investors lodging indicative orders surpassing the offering size during bookbuilding. — Reuters SYDNEY: Virgin Australia shares rallied 8.3% yesterday, after its A$685mil (US$439mil) initial public offering (IPO), a transaction dealmakers hope will revive a subdued listings market. The airline sold 236.2 million shares at A$2.90 each, valuing it at A$2.32bil on a fully diluted basis. The stock began trading at A$3.14, outpacing a 1.2% gain in the Australian benchmark S&P/ASX200. Virgin's listing comes amid operational disruptions, with the airline diverting two Qatar-bound flights to India and Oman, according to flight tracking website FlightRadar24. Qatar temporarily closed its airspace ahead of Iran launching missiles at a US base in the state. Virgin did not immediately respond to a request for comment from Reuters. Shares of Qantas, the main rival to Virgin Australia, climbed 4% yesterday following a 7% drop in global oil prices the previous day, after Iran took no action to disrupt oil and gas tanker traffic through the Strait of Hormuz. Virgin disclosed in an exchange filing that it has hedged 98% of its anticipated fuel usage in Brent crude oil at a cap of US$70 per barrel for the first half of 2026. It has hedged 86% of its anticipated fuel usage at the same price in the second half. 'Four years ago, with the help of Bain Capital, we set out to transform Virgin into a simpler, more focused company with a clear view on how we are going to serve our customers and how we are going to win in the Australian domestic market,' Dave Emerson, Virgin Australia chief executive, said at a listing ceremony in Sydney. Virgin, which is Australia's second-largest airline by market share after Qantas Airways, was delisted in 2020 after private equity giant Bain Capital rescued it from administration. Bain, which bought Virgin for A$3.5bil including liabilities, will see its stake reduced to 39.4% from about 70%, while Qatar Airways, which recently bought into the airline, will retain 23%, the IPO prospectus showed. The IPO attracted strong demand, with institutional investors lodging indicative orders surpassing the offering size during bookbuilding, according to a term sheet reviewed by Reuters. The shares being priced at an almost 30% discount to those of Qantas were an incentive to buy, fund managers said. Virgin has a domestic flight market share of 34.4% as of March versus Qantas' 37.5%, a report from the Australian Competition and Consumer Commission showed. 'From our perspective, the IPO pricing offered an attractive discount to Qantas, allowing room for shareholders to benefit from Virgin's operational improvement targets and structural tailwinds like the rise of premium ticket demand,' said Jun Bei Liu, founder of Ten Cap, which is a Virgin cornerstone investor. 'Virgin's domestic focus and hedged fuel position provide resilience amid geopolitical and commodity market risks.' Virgin pared back its international business under Bain's ownership. It has resumed long-haul flights to Doha through a lease agreement with state-owned Qatar Airways. — Reuters


Malaysian Reserve
4 hours ago
- Malaysian Reserve
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ — Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Indaptus Therapeutics, Inc. (NASDAQ: INDP), Perspective Therapeutics, Inc. (NYSE-American: CATX), SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), and Autolus Therapeutics plc (NASDAQ: AUTL). Analysts at Nova One Advisor are currently projecting the global oncology drug market to hit US$366.24 billion by 2034, expanding at a 7.4% CAGR. Others are even more optimistic, with ResearchAndMarkets estimating the sector will reach US$866.1 billion by 2034, growing at a 10.8% CAGR, and Vision Research Reports anticipating the market will top US$903.81 billion by the same year, driven by accelerating demand for advanced diagnostics and treatments. All this points to an optimal timing period for breakout cancer stocks. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress. Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients,' said Jared Kelly, CEO of Oncolytics Biotech. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.' Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers. Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential. Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations. In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation. Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs. 'Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,' said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. 'We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors.' Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development. As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction. Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Indaptus Therapeutics, Inc. (NASDAQ: INDP) recently initiated dosing in a Phase 1b/2 study arm testing its lead candidate Decoy20 with PD-1 inhibitor tislelizumab in advanced solid tumors. 'This is an important milestone in our clinical development,' said Jeffrey Meckler, CEO of Indaptus. 'We have long believed the Decoy platform has the potential to be a game-changing approach to treating solid tumors.' The combination is being evaluated in patients previously treated with checkpoint inhibitors or with tumor types typically unresponsive to immunotherapy. Early preclinical findings showed Decoy20 could synergize with PD-1 blockade to activate stronger anti-tumor immunity. The trial will monitor safety and preliminary signals of efficacy before broader enrollment. Perspective Therapeutics, Inc. (NYSE-American: CATX) has recently opened enrollment for Cohort 3 of its Phase 1/2a trial testing [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors. 'We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial,' commented Markus Puhlmann, Chief Medical Officer of Perspective. 'We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs.' The newly approved dose level represents a 20% increase over the previous cohort and will be evaluated for safety and early signals of efficacy. Interim results presented at American Society of Clinical Oncology (ASCO) Annual Meeting and Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting showed evidence of anti-tumor activity and favorable tolerability at lower doses. The company expects to submit additional clinical updates in the second half of 2025 following extended patient follow-up. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) recently presented new preclinical data at the 2025 ASCO Annual Meeting showing that its CDK9 inhibitor SLS009 demonstrated potent activity in ASXL1-mutated colorectal cancer cell lines. 'These results provide strong rationale for continued advancement of SLS009 as a potential treatment for ASXL1-mutated cancers,' said Dr. Dragan Cicic, Senior Vice President, Chief Development Officer at SELLAS. 'The ability to selectively target ASXL1-driven tumors at concentrations well below the known safety threshold opens the door for tolerable and effective therapy. Based on the findings, we believe that ASXL1 mutation status could serve as a potential biomarker for response to SLS009 inhibition, which may allow us to further refine patient selection and improve outcomes. We look forward to presenting these results at ASCO.' In the study, 75% of lines with ASXL1 frameshift mutations responded at low nanomolar concentrations, while no response was observed in wild-type lines. These findings suggest that ASXL1 mutation status may serve as a potential biomarker for patient selection. Autolus Therapeutics plc (NASDAQ: AUTL) has released updated results from its FELIX study, showing that obe-cel, a next-generation CAR T cell therapy, may provide long-term remission for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). With a median follow-up of nearly 33 months, more than 50% of patients were still in remission at 24 months, and 38% had not needed any additional therapy. 'Obe-cel's durability of response without any subsequent therapy in two out of every five responders is a key factor leading the transformation of therapy for adult r/r B-ALL patients. At a median follow up of 33 months, we are encouraged to see a continuation of the long-term plateau we observed at the last data cut,' said Dr. Christian Itin, CEO of Autolus. 'A well-tolerated, effective, durable treatment option for ALL patients who often have a poor prognosis and have had multiple prior treatments is of significant clinical benefit.' The data suggested obe-cel could serve as a standalone option for some patients, reducing the need for transplants or further treatment. The company also reported a strong safety profile and plans to continue advancing obe-cel as a potential cornerstone in adult B-ALL care. Source: CONTACT: Equity Insider info@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Video – – – View original content:


Rakyat Post
5 hours ago
- Rakyat Post
From Courtroom To Cork In Bangsar: The Lawyer Who Traded Briefs For Bordeaux
Subscribe to our FREE Lau Jia-Sen had it all figured out – law degree, CLP certification, four solid years building a legal practice. The 36-year-old from Old Klang Road was living the Malaysian dream: steady paycheck, predictable hours, respectable profession. Then, in April 2024, everything changed. 'If I'd discovered my passion earlier, I would never have studied law,' Lau told TRP, sipping a cup of artisanal coffee at Juno, his gastro wine bar tucked away in a quiet corner of Bangsar. Named after the Roman goddess of protection and marriage (Hera in Greek mythology), the venue seems fitting for someone who's found his true calling. It's the kind of confession that makes parents everywhere clutch their pearls, but for this former lawyer-turned-sommelier, it's pure liberation. The Great Career Plot Twist The transition wasn't exactly overnight. While building his legal career, Lau was moonlighting as a barista – perhaps the universe's way of dropping hints about his true calling. Fast forward to today, and he's running Juno, a spot that's part wine sanctuary, part culinary playground, where natural wines meet European-Asian fusion in the most unpretentious way possible. 'Wine can be intimidating for the uninitiated,' Lau explains, describing his approach to hospitality. We want customers to appreciate what we have without feeling like they need a PhD in viticulture. His 60-70 label collection focuses heavily on natural wines – think free-range chicken, but for grapes. Minimal intervention, no chemicals, just fruit doing what fruit does best in ideal natural environments. More Than Just Grape Expectations The beauty of Juno lies in its refusal to take itself too seriously. Sure, they've got your classic French three to four-course meals and sophisticated wine flights, but they've also paired char kuay teow and nasi lemak with wine because why not? It's this kind of 'let's-see-what-happens' energy that keeps things exciting. The menu reads like a greatest hits of comfort food with a twist – European-Asian fusion pasta, fresh oysters, quality steaks, and hot doughnuts for dessert. Lau's personal favourite is the pepetama pasta, a Japanese take on carbonara that's 'salty, cheesy, savoury, a bit spicy, very Asian.' It's the kind of dish that makes you question why anyone ever thought fusion was a dirty word. Double Life, Double Trouble But wait, there's more. Lau also runs The plan? Merge the two operations at Juno's location – café by day, wine bar by night. It's ambitious, slightly crazy, and exactly the kind of move you'd expect from someone who went from practising law to curating wine lists in the span of a year. 'I knew nothing about wine a year ago,' Lau confesses. I do a lot of reading, ask wine professionals, do tastings, write notes. It's the kind of crash course that would make most people's heads spin, but Lau seems to thrive on the chaos. (Pix: Instagram/@junobangsar) The New Normal These days, Lau wears more hats than a vintage shop – operations manager, front of house, sommelier, cook, HR department, event planner, business development guru, menu curator, and doughnut maker. It's exhausting just reading the list, but he wouldn't have it any other way. I miss the predictability of a lawyer's paycheck, but I relish wearing all sorts of hats now. With several full-time staff members helping out and partners covering when he's away, Juno has become more than just a business – it's a community. Wine O'Clock Wisdom The monthly steak and wine nights (RM88 for grass-fed Angus beef and a glass of wine) perfectly capture Juno's philosophy: wine shouldn't be reserved for special occasions. It should be woven into the fabric of daily life, paired with whatever makes you happy, whether that's a perfectly cooked steak or a late-night bowl of noodles. Open daily except Tuesdays (6 pm-12 am weekdays, until 1 am weekends), Juno operates in that competitive Bangsar landscape where every corner seems to house another trendy spot. However, Lau has found his niche among natural wine enthusiasts and regular customers who appreciate his unpretentious approach to a good life. The Pour Decision When he's not busy revolutionising Bangsar's wine scene, Lau unwinds with pickleball. His current wine obsession? Matassa—meaning 'forest' in Catalan—offers fruity, floral, and mineral notes that create a journey in your mouth, said Lau. Maybe fruit and floral chamomile on the first sip, then towards the end, some sensation in your mouth. That's the beauty of natural wine. It's the kind of passionate description that makes you understand why someone would abandon a stable legal career for the unpredictable world of hospitality. Sometimes, the most important thing is just having the courage to try. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.